Prophage exotoxins enhance colonization fitness in epidemic scarlet fever-causing Streptococcus pyogenes.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
06 10 2020
Historique:
received: 21 12 2019
accepted: 01 09 2020
entrez: 7 10 2020
pubmed: 8 10 2020
medline: 30 10 2020
Statut: epublish

Résumé

The re-emergence of scarlet fever poses a new global public health threat. The capacity of North-East Asian serotype M12 (emm12) Streptococcus pyogenes (group A Streptococcus, GAS) to cause scarlet fever has been linked epidemiologically to the presence of novel prophages, including prophage ΦHKU.vir encoding the secreted superantigens SSA and SpeC and the DNase Spd1. Here, we report the molecular characterization of ΦHKU.vir-encoded exotoxins. We demonstrate that streptolysin O (SLO)-induced glutathione efflux from host cellular stores is a previously unappreciated GAS virulence mechanism that promotes SSA release and activity, representing the first description of a thiol-activated bacterial superantigen. Spd1 is required for resistance to neutrophil killing. Investigating single, double and triple isogenic knockout mutants of the ΦHKU.vir-encoded exotoxins, we find that SpeC and Spd1 act synergistically to facilitate nasopharyngeal colonization in a mouse model. These results offer insight into the pathogenesis of scarlet fever-causing GAS mediated by prophage ΦHKU.vir exotoxins.

Identifiants

pubmed: 33024089
doi: 10.1038/s41467-020-18700-5
pii: 10.1038/s41467-020-18700-5
pmc: PMC7538557
doi:

Substances chimiques

Bacterial Proteins 0
Exotoxins 0
Streptolysins 0
Superantigens 0
streptolysin O 0
Glutathione GAN16C9B8O

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5018

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : CIHR
Pays : Canada

Références

Katz, A. R. & Morens, D. M. Severe streptococcal infections in historical perspective. Clin. Infect. Dis. 14, 298–307 (1992).
pubmed: 1571445 doi: 10.1093/clinids/14.1.298
Morens, D. M., Folkers, G. K. & Fauci, A. S. The challenge of emerging and re-emerging infectious diseases. Nature 430, 242–249 (2004).
pubmed: 15241422 pmcid: 7094993 doi: 10.1038/nature02759
Luk, E. Y. et al. Scarlet fever epidemic, Hong Kong, 2011. Emerg. Infect. Dis. 18, 1658–1661 (2012).
pubmed: 23018120 pmcid: 3471614 doi: 10.3201/eid1810.111900
Tse, H. et al. Molecular characterization of the 2011 Hong Kong scarlet fever outbreak. J. Infect. Dis. 206, 341–351 (2012).
pubmed: 22615319 pmcid: 4125623 doi: 10.1093/infdis/jis362
Turner, C. E. et al. Scarlet fever upsurge in England and molecular-genetic analysis in North-West London, 2014. Emerg. Infect. Dis. 22, 1075–1078 (2016).
pubmed: 27192393 pmcid: 4880090 doi: 10.3201/eid2206.151726
Chalker, V. et al. Genome analysis following a national increase in scarlet fever in England 2014. BMC Genomics 18, 224 (2017).
pubmed: 28283023 pmcid: 5345146 doi: 10.1186/s12864-017-3603-z
Park, D. W. et al. Incidence and characteristics of scarlet fever, South Korea, 2008-2015. Emerg. Infect. Dis. 23, 658–661 (2017).
pubmed: 28322696 pmcid: 5367408 doi: 10.3201/eid2304.160773
Liu, Y. et al. Resurgence of scarlet fever in China: a 13-year population-based surveillance study. Lancet Infect. Dis. 18, 903–912 (2018).
pubmed: 29858148 pmcid: 7185785 doi: 10.1016/S1473-3099(18)30231-7
Lamagni, T. et al. Resurgence of scarlet fever in England, 2014-16: a population-based surveillance study. Lancet Infect. Dis. 18, 180–187 (2018).
pubmed: 29191628 doi: 10.1016/S1473-3099(17)30693-X
Lynskey, N. N. et al. Emergence of dominant toxigenic M1T1 Streptococcus pyogenes clone during increased scarlet fever activity in England: a population-based molecular epidemiological study. Lancet Infect. Dis. 19, 1209–1218 (2019).
pubmed: 31519541 pmcid: 6838661 doi: 10.1016/S1473-3099(19)30446-3
Yung, C. F. & Thoon, K. C. A 12 year outbreak of scarlet fever in Singapore. Lancet Infect. Dis. 18, 942 (2018).
pubmed: 30152353 doi: 10.1016/S1473-3099(18)30464-X
Walker, M. J. et al. Detection of epidemic scarlet fever group A Streptococcus in Australia. Clin. Infect. Dis. 69, 1232–1234 (2019).
pubmed: 30721938 doi: 10.1093/cid/ciz099
Demczuk, W., Martin, I., Domingo, F. R., MacDonald, D. & Mulvey, M. R. Identification of Streptococcus pyogenes M1UK clone in Canada. Lancet Infect. Dis. 19, 1284–1285 (2019).
pubmed: 31782392 doi: 10.1016/S1473-3099(19)30622-X
Walker, M. J. & Brouwer, S. Scarlet fever makes a comeback. Lancet Infect. Dis. 18, 128–129 (2018).
pubmed: 29191627 doi: 10.1016/S1473-3099(17)30694-1
Davies, M. R. et al. Emergence of scarlet fever Streptococcus pyogenes emm12 clones in Hong Kong is associated with toxin acquisition and multidrug resistance. Nat. Genet. 47, 84–87 (2015).
pubmed: 25401300 doi: 10.1038/ng.3147
Ben Zakour, N. L. et al. Transfer of scarlet fever-associated elements into the group A Streptococcus M1T1 clone. Sci. Rep. 5, 15877 (2015).
pubmed: 26522788 pmcid: 4629146 doi: 10.1038/srep15877
You, Y. et al. Scarlet fever epidemic in China caused by Streptococcus pyogenes serotype M12: epidemiologic and molecular analysis. EBioMedicine 28, 128–135 (2018).
pubmed: 29342444 pmcid: 5835554 doi: 10.1016/j.ebiom.2018.01.010
Silva-Costa, C., Carrico, J. A., Ramirez, M. & Melo-Cristino, J. Scarlet fever is caused by a limited number of Streptococcus pyogenes lineages and is associated with the exotoxin genes ssa, speA and speC. Pediatr. Infect. Dis. J. 33, 306–310 (2014).
pubmed: 24168973 doi: 10.1097/INF.0000000000000088
Proft, T. & Fraser, J. D. In Streptococcus pyogenes: Basic Biology to Clinical Manifestations (eds Ferretti, J. J., Stevens, D. L. & Fischetti, V. A.) 445–486 (Univ. Oklahoma Health Sciences Center, 2016).
Kasper, K. J. et al. Bacterial superantigens promote acute nasopharyngeal infection by Streptococcus pyogenes in a human MHC Class II-dependent manner. PLoS Pathog. 10, e1004155 (2014).
pubmed: 24875883 pmcid: 4038607 doi: 10.1371/journal.ppat.1004155
Zeppa, J. J. et al. Nasopharyngeal infection by Streptococcus pyogenes requires superantigen-responsive Vbeta-specific T cells. Proc. Natl Acad. Sci. USA 114, 10226–10231 (2017).
pubmed: 28794279 doi: 10.1073/pnas.1700858114
Fossum, G. H., Lindbaek, M., Gjelstad, S., Dalen, I. & Kvaerner, K. J. Are children carrying the burden of broad-spectrum antibiotics in general practice? Prescription pattern for paediatric outpatients with respiratory tract infections in Norway. BMJ Open 3, e002285 (2013).
pubmed: 23299114 pmcid: 3549229 doi: 10.1136/bmjopen-2012-002285
Bisno, A. L. Acute pharyngitis. N. Engl. J. Med. 344, 205–211 (2001).
pubmed: 11172144 doi: 10.1056/NEJM200101183440308
Min, Y. H., Kwon, A. R., Yoon, E. J., Shim, M. J. & Choi, E. C. Translational attenuation and mRNA stabilization as mechanisms of erm(B) induction by erythromycin. Antimicrob. Agents Chemother. 52, 1782–1789 (2008).
pubmed: 18299414 pmcid: 2346635 doi: 10.1128/AAC.01376-07
Banks, D. J., Lei, B. & Musser, J. M. Prophage induction and expression of prophage-encoded virulence factors in group A Streptococcus serotype M3 strain MGAS315. Infect. Immun. 71, 7079–7086 (2003).
pubmed: 14638798 pmcid: 308911 doi: 10.1128/IAI.71.12.7079-7086.2003
Morita, A., Imada, Y., Igarashi, H. & Yutsudo, T. Serologic evidence that streptococcal superantigens are not involved in the pathogenesis of Kawasaki disease. Microbiol Immunol. 41, 895–900 (1997).
pubmed: 9444333 doi: 10.1111/j.1348-0421.1997.tb01947.x
Norrby-Teglund, A. et al. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J. Immunol. 156, 3057–3064 (1996).
pubmed: 8609429
Schrage, B., Duan, G., Yang, L. P., Fraser, J. D. & Proft, T. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome. Clin. Infect. Dis. 43, 743–746 (2006).
pubmed: 16912949 doi: 10.1086/507037
Broudy, T. B., Pancholi, V. & Fischetti, V. A. Induction of lysogenic bacteriophage and phage-associated toxin from group A streptococci during coculture with human pharyngeal cells. Infect. Immun. 69, 1440–1443 (2001).
pubmed: 11179310 pmcid: 98039 doi: 10.1128/IAI.69.3.1440-1443.2001
Broudy, T. B., Pancholi, V. & Fischetti, V. A. The in vitro interaction of Streptococcus pyogenes with human pharyngeal cells induces a phage-encoded extracellular DNase. Infect. Immun. 70, 2805–2811 (2002).
pubmed: 12010966 pmcid: 127989 doi: 10.1128/IAI.70.6.2805-2811.2002
Sundberg, E. J. et al. Structures of two streptococcal superantigens bound to TCR beta chains reveal diversity in the architecture of T cell signaling complexes. Structure 10, 687–699 (2002).
pubmed: 12015151 doi: 10.1016/S0969-2126(02)00759-1
De Marzi, M. C. et al. Cloning, expression and interaction of human T-cell receptors with the bacterial superantigen SSA. Eur. J. Biochem. 271, 4075–4083 (2004).
pubmed: 15479236 doi: 10.1111/j.1432-1033.2004.04345.x
Proft, T., Arcus, V. L., Handley, V., Baker, E. N. & Fraser, J. D. Immunological and biochemical characterization of streptococcal pyrogenic exotoxins I and J (SPE-I and SPE-J) from Streptococcus pyogenes. J. Immunol. 166, 6711–6719 (2001).
pubmed: 11359827 doi: 10.4049/jimmunol.166.11.6711
Li, P. L., Tiedemann, R. E., Moffat, S. L. & Fraser, J. D. The superantigen streptococcal pyrogenic exotoxin C (SPE-C) exhibits a novel mode of action. J. Exp. Med. 186, 375–383 (1997).
pubmed: 9236189 pmcid: 2199005 doi: 10.1084/jem.186.3.375
Proft, T., Moffatt, S. L., Berkahn, C. J. & Fraser, J. D. Identification and characterization of novel superantigens from Streptococcus pyogenes. J. Exp. Med. 189, 89–102 (1999).
pubmed: 9874566 pmcid: 1887688 doi: 10.1084/jem.189.1.89
Tweten, R. K. Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. Infect. Immun. 73, 6199–6209 (2005).
pubmed: 16177291 pmcid: 1230961 doi: 10.1128/IAI.73.10.6199-6209.2005
Schafer, F. Q. & Buettner, G. R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med. 30, 1191–1212 (2001).
pubmed: 11368918 pmcid: 11368918 doi: 10.1016/S0891-5849(01)00480-4
Alouf, J. E. Streptococcal toxins (streptolysin O, streptolysin S, erythrogenic toxin). Pharm. Ther. 11, 661–717 (1980).
doi: 10.1016/0163-7258(80)90045-5
Bessen, D. E. Tissue tropisms in group A Streptococcus: what virulence factors distinguish pharyngitis from impetigo strains? Curr. Opin. Infect. Dis. 29, 295–303 (2016).
pubmed: 26895573 pmcid: 5373551 doi: 10.1097/QCO.0000000000000262
Aziz, R. K. et al. Mosaic prophages with horizontally acquired genes account for the emergence and diversification of the globally disseminated M1T1 clone of Streptococcus pyogenes. J. Bacteriol. 187, 3311–3318 (2005).
pubmed: 15866915 pmcid: 1112019 doi: 10.1128/JB.187.10.3311-3318.2005
Sumby, P. et al. Evolutionary origin and emergence of a highly successful clone of serotype M1 group A Streptococcus involved multiple horizontal gene transfer events. J. Infect. Dis. 192, 771–782 (2005).
pubmed: 16088826 doi: 10.1086/432514
Walker, M. J. et al. DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nat. Med. 13, 981–985 (2007).
pubmed: 17632528 doi: 10.1038/nm1612
Afshar, B. et al. Enhanced nasopharyngeal infection and shedding associated with an epidemic lineage of emm3 group A Streptococcus. Virulence 8, 1390–1400 (2017).
pubmed: 28459299 pmcid: 5711448 doi: 10.1080/21505594.2017.1325070
Brinkmann, V. et al. Neutrophil extracellular traps kill bacteria. Science 303, 1532–1535 (2004).
pubmed: 15001782 doi: 10.1126/science.1092385
Buchanan, J. T. et al. DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps. Curr. Biol. 16, 396–400 (2006).
pubmed: 16488874 doi: 10.1016/j.cub.2005.12.039
Park, H. S. et al. Primary induction of CD4 T cell responses in nasal associated lymphoid tissue during group A streptococcal infection. Eur. J. Immunol. 34, 2843–2853 (2004).
pubmed: 15368301 doi: 10.1002/eji.200425242
Wang, B. et al. Induction of TGF-beta1 and TGF-beta1-dependent predominant Th17 differentiation by group A streptococcal infection. Proc. Natl Acad. Sci. USA 107, 5937–5942 (2010).
pubmed: 20231435 doi: 10.1073/pnas.0904831107
Chen, Z. et al. Humanized transgenic mice expressing HLA DR4-DQ3 haplotype: reconstitution of phenotype and HLA-restricted T-cell responses. Tissue Antigens 68, 210–219 (2006).
pubmed: 16948641 doi: 10.1111/j.1399-0039.2006.00656.x
Timmer, A. M. et al. Streptolysin O promotes group A Streptococcus immune evasion by accelerated macrophage apoptosis. J. Biol. Chem. 284, 862–871 (2009).
pubmed: 19001420 pmcid: 2613605 doi: 10.1074/jbc.M804632200
Uchiyama, S. et al. Streptolysin O rapidly impairs neutrophil oxidative burst and antibacterial responses to group A Streptococcus. Front. Immunol. 6, 581 (2015).
pubmed: 26635795 pmcid: 4644796 doi: 10.3389/fimmu.2015.00581
Zhu, L. et al. Contribution of secreted NADase and streptolysin O to the pathogenesis of epidemic serotype M1 Streptococcus pyogenes infections. Am. J. Pathol. 187, 605–613 (2017).
pubmed: 28034602 pmcid: 5397666 doi: 10.1016/j.ajpath.2016.11.003
Hsieh, Y. C. & Huang, Y. C. Scarlet fever outbreak in Hong Kong, 2011. J. Microbiol. Immunol. Infect. 44, 409–411 (2011).
pubmed: 21873124 doi: 10.1016/j.jmii.2011.07.003
Chen, M. et al. Outbreak of scarlet fever associated with emm12 type group A Streptococcus in 2011 in Shanghai, China. Pediatr. Infect. Dis. J. 31, e158–e162 (2012).
pubmed: 22531238 doi: 10.1097/INF.0b013e31825874f3
Lau, E. H., Nishiura, H., Cowling, B. J., Ip, D. K. & Wu, J. T. Scarlet fever outbreak, Hong Kong, 2011. Emerg. Infect. Dis. 18, 1700–1702 (2012).
pubmed: 23017843 pmcid: 3471616 doi: 10.3201/eid1810.120062
Yang, P. et al. Characteristics of group A Streptococcus strains circulating during scarlet fever epidemic, Beijing, China, 2011. Emerg. Infect. Dis. 19, 909–915 (2013).
pubmed: 23735582 pmcid: 4816378 doi: 10.3201/eid1906.121020
Brouwer, S., Lacey, J. A., You, Y., Davies, M. R. & Walker, M. J. Scarlet fever changes its spots. Lancet Infect. Dis. 19, 1154–1155 (2019).
pubmed: 31519542 doi: 10.1016/S1473-3099(19)30494-3
Brosnahan, A. J., Mantz, M. J., Squier, C. A., Peterson, M. L. & Schlievert, P. M. Cytolysins augment superantigen penetration of stratified mucosa. J. Immunol. 182, 2364–2373 (2009).
pubmed: 19201891 pmcid: 2805182 doi: 10.4049/jimmunol.0803283
Veeravalli, K., Boyd, D., Iverson, B. L., Beckwith, J. & Georgiou, G. Laboratory evolution of glutathione biosynthesis reveals natural compensatory pathways. Nat. Chem. Biol. 7, 101–105 (2011).
pubmed: 21186348 doi: 10.1038/nchembio.499
Brenot, A., King, K. Y., Janowiak, B., Griffith, O. & Caparon, M. G. Contribution of glutathione peroxidase to the virulence of Streptococcus pyogenes. Infect. Immun. 72, 408–413 (2004).
pubmed: 14688122 pmcid: 344014 doi: 10.1128/IAI.72.1.408-413.2004
Reniere, M. L. Reduce, induce, thrive: bacterial redox sensing during pathogenesis. J. Bacteriol. 200, e00128–18 (2018).
pubmed: 29891640 pmcid: 6088161 doi: 10.1128/JB.00128-18
Ku, J. W. & Gan, Y. H. Modulation of bacterial virulence and fitness by host glutathione. Curr. Opin. Microbiol. 47, 8–13 (2018).
pubmed: 30396015 doi: 10.1016/j.mib.2018.10.004
Commons, R. et al. Superantigen genes in group A streptococcal isolates and their relationship with emm types. J. Med. Microbiol. 57, 1238–1246 (2008).
pubmed: 18809552 doi: 10.1099/jmm.0.2008/001156-0
Chochua, S. et al. Emergent invasive group A Streptococcus dysgalactiae subsp. equisimilis, United States, 2015-2018. Emerg. Infect. Dis. 25, 1543–1547 (2019).
pubmed: 31158071 pmcid: 6649341 doi: 10.3201/eid2508.181758
Barnett, T. C., Daw, J. N., Walker, M. J. & Brouwer, S. In Group A Streptococcus: Methods and Protocols (eds Proft, T. & Loh, J.) 59–69 (Springer, 2020).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281 pmcid: 4302049
Brouwer, S. et al. Endopeptidase PepO regulates the SpeB cysteine protease and is essential for the virulence of invasive M1T1 Streptococcus pyogenes. J. Bacteriol. 200, e00654–17 (2018).
pubmed: 29378883 pmcid: 5869480 doi: 10.1128/JB.00654-17
Korczynska, J. E., Turkenburg, J. P. & Taylor, E. J. The structural characterization of a prophage-encoded extracellular DNase from Streptococcus pyogenes. Nucleic Acids Res. 40, 928–938 (2012).
pubmed: 21948797 doi: 10.1093/nar/gkr789
Rivera-Hernandez, T. et al. Differing efficacies of lead group A streptococcal vaccine candidates and full-length M protein in cutaneous and invasive disease models. mBio 7, e00618–16 (2016).
pubmed: 27302756 pmcid: 4916377 doi: 10.1128/mBio.00618-16
Rahman, A. K. M. N. U. et al. Molecular basis of TCR selectivity, cross-reactivity, and allelic discrimination by a bacterial superantigen: integrative functional and energetic mapping of the SpeC-V beta 2.1 molecular interface. J. Immunol. 177, 8595–8603 (2006).
pubmed: 17142758 doi: 10.4049/jimmunol.177.12.8595
Australian Government National Health and Medical Research Council. National Statement on Ethical Conduct In Human Research (NHMRC, 2015).
Palmer, M. The family of thiol-activated, cholesterol-binding cytolysins. Toxicon 39, 1681–1689 (2001).
pubmed: 11595631 doi: 10.1016/S0041-0101(01)00155-6
Cywes Bentley, C., Hakansson, A., Christianson, J. & Wessels, M. R. Extracellular group A Streptococcus induces keratinocyte apoptosis by dysregulating calcium signalling. Cell Microbiol. 7, 945–955 (2005).
pubmed: 15953027 doi: 10.1111/j.1462-5822.2005.00525.x

Auteurs

Stephan Brouwer (S)

Australian Infectious Diseases Research Centre and School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD, Australia.

Timothy C Barnett (TC)

Australian Infectious Diseases Research Centre and School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD, Australia.
Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Nedlands, WA, Australia.

Diane Ly (D)

Illawarra Health and Medical Research Institute, Wollongong, NSW, Australia.
Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW, Australia.

Katherine J Kasper (KJ)

Department of Microbiology and Immunology and the Centre for Human Immunology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.

David M P De Oliveira (DMP)

Australian Infectious Diseases Research Centre and School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD, Australia.

Tania Rivera-Hernandez (T)

Australian Infectious Diseases Research Centre and School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD, Australia.

Amanda J Cork (AJ)

Australian Infectious Diseases Research Centre and School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD, Australia.

Liam McIntyre (L)

Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.

Magnus G Jespersen (MG)

Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.

Johanna Richter (J)

Australian Infectious Diseases Research Centre and School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD, Australia.

Benjamin L Schulz (BL)

Australian Infectious Diseases Research Centre and School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD, Australia.

Gordon Dougan (G)

The Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.

Victor Nizet (V)

Department of Pediatrics, University of California San Diego, La Jolla, CA, USA.

Kwok-Yung Yuen (KY)

State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, Hong Kong, China.
Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, Hong Kong, China.
Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, Hong Kong, China.

Yuanhai You (Y)

State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Centre for Disease Control and Prevention, Beijing, 102206, China.

John K McCormick (JK)

Department of Microbiology and Immunology and the Centre for Human Immunology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Lawson Health Research Institute, London, ON, Canada.

Martina L Sanderson-Smith (ML)

Illawarra Health and Medical Research Institute, Wollongong, NSW, Australia.
Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW, Australia.

Mark R Davies (MR)

Australian Infectious Diseases Research Centre and School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD, Australia.
Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.

Mark J Walker (MJ)

Australian Infectious Diseases Research Centre and School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD, Australia. mark.walker@uq.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH